Lisa B VanWagner1,2, Jane E Wilcox1,3, Laura A Colangelo1, Donald M Lloyd-Jones1,3, J Jeffrey Carr4, Joao A Lima5, Cora E Lewis6, Mary E Rinella2, Sanjiv J Shah3. 1. Departments of Preventive Medicine and Medicine, Northwestern University, Chicago, IL. 2. Division of Gastroenterology & Hepatology, Northwestern University, Chicago, IL. 3. Division of Cardiology, Northwestern University, Chicago, IL. 4. Departments of Radiology, Cardiovascular Medicine and Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN. 5. Departments of Medicine and Radiology, Johns Hopkins University School of Medicine, Baltimore, MD. 6. Department of Medicine, Division of Preventive Medicine, University of Alabama Birmingham School of Medicine, Birmingham, AL.
Abstract
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity-related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown. We performed a cross-sectional analysis of 2,713 participants from the multicenter, community-based Coronary Artery Risk Development in Young Adults (CARDIA) study who underwent concurrent computed tomography (CT) quantification of liver fat and comprehensive echocardiography with myocardial strain measured by speckle tracking during the Year-25 examination (age, 43-55 years; 58.8% female and 48.0% black). NAFLD was defined as liver attenuation ≤40 Hounsfield units after excluding other causes of liver fat. Subclinical left ventricular (LV) systolic dysfunction was defined using values of absolute peak global longitudinal strain (GLS). Diastolic dysfunction was defined using Doppler and tissue Doppler imaging markers. Prevalence of NAFLD was 10.0%. Participants with NAFLD had lower early diastolic relaxation (e') velocity (10.8 ± 2.6 vs. 11.9 ± 2.8 cm/s), higher LV filling pressure (E/e' ratio: 7.7 ± 2.6 vs. 7.0 ± 2.3), and worse absolute GLS (14.2 ± 2.4% vs. 15.2 ± 2.4%) than non-NAFLD (P < 0.0001 for all). When adjusted for HF risk factors or body mass index, NAFLD remained associated with subclinical myocardial remodeling and dysfunction (P < 0.01). The association of NAFLD with e' velocity (β = -0.36 [standard error = 0.15] cm/s; P = 0.02), E/e' ratio (β = 0.35 [0.16]; P = 0.03), and GLS (β = -0.42 [0.18]%; P = 0.02) was attenuated after controlling for visceral adipose tissue. Effect modification by race and sex was not observed. CONCLUSIONS: NAFLD is independently associated with subclinical myocardial remodeling and dysfunction and provides further insight into a possible link between NAFLD and HF.
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity-related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown. We performed a cross-sectional analysis of 2,713 participants from the multicenter, community-based Coronary Artery Risk Development in Young Adults (CARDIA) study who underwent concurrent computed tomography (CT) quantification of liver fat and comprehensive echocardiography with myocardial strain measured by speckle tracking during the Year-25 examination (age, 43-55 years; 58.8% female and 48.0% black). NAFLD was defined as liver attenuation ≤40 Hounsfield units after excluding other causes of liver fat. Subclinical left ventricular (LV) systolic dysfunction was defined using values of absolute peak global longitudinal strain (GLS). Diastolic dysfunction was defined using Doppler and tissue Doppler imaging markers. Prevalence of NAFLD was 10.0%. Participants with NAFLD had lower early diastolic relaxation (e') velocity (10.8 ± 2.6 vs. 11.9 ± 2.8 cm/s), higher LV filling pressure (E/e' ratio: 7.7 ± 2.6 vs. 7.0 ± 2.3), and worse absolute GLS (14.2 ± 2.4% vs. 15.2 ± 2.4%) than non-NAFLD (P < 0.0001 for all). When adjusted for HF risk factors or body mass index, NAFLD remained associated with subclinical myocardial remodeling and dysfunction (P < 0.01). The association of NAFLD with e' velocity (β = -0.36 [standard error = 0.15] cm/s; P = 0.02), E/e' ratio (β = 0.35 [0.16]; P = 0.03), and GLS (β = -0.42 [0.18]%; P = 0.02) was attenuated after controlling for visceral adipose tissue. Effect modification by race and sex was not observed. CONCLUSIONS: NAFLD is independently associated with subclinical myocardial remodeling and dysfunction and provides further insight into a possible link between NAFLD and HF.
Authors: Yoshihisa Kodama; Chaan S Ng; Tsung T Wu; Gregory D Ayers; Steven A Curley; Eddie K Abdalla; Jean Nicolas Vauthey; Chusilp Charnsangavej Journal: AJR Am J Roentgenol Date: 2007-05 Impact factor: 3.959
Authors: Mikko Kankaanpää; Hanna-Riikka Lehto; Jussi P Pärkkä; Markku Komu; Antti Viljanen; Ele Ferrannini; Juhani Knuuti; Pirjo Nuutila; Riitta Parkkola; Patricia Iozzo Journal: J Clin Endocrinol Metab Date: 2006-08-22 Impact factor: 5.958
Authors: Bum J Park; Yoon J Kim; Dong H Kim; Won Kim; Yong J Jung; Jung H Yoon; Chung Y Kim; Young M Cho; Se H Kim; Kyoung B Lee; Ja J Jang; Hyo S Lee Journal: J Gastroenterol Hepatol Date: 2007-11-07 Impact factor: 4.029
Authors: Riikka Lautamäki; Ronald Borra; Patricia Iozzo; Markku Komu; Terho Lehtimäki; Marko Salmi; Sirpa Jalkanen; K E Juhani Airaksinen; Juhani Knuuti; Riitta Parkkola; Pirjo Nuutila Journal: Am J Physiol Endocrinol Metab Date: 2006-02-14 Impact factor: 4.310
Authors: Justin McNair Canada; Antonio Abbate; Rebecca Collen; Hayley Billingsley; Leo Francis Buckley; Salvatore Carbone; Cory Ross Trankle; Michael Ola Idowu; Dinesh Kadariya; Benjamin Van Tassell; Arun Jayant Sanyal; Mohammad Shadab Siddiqui Journal: Am J Cardiol Date: 2018-11-06 Impact factor: 2.778
Authors: Mohammad R Ostovaneh; Bharath Ambale-Venkatesh; Tomoki Fuji; Hooman Bakhshi; Ravi Shah; Venkatesh L Murthy; Russell P Tracy; Eliseo Guallar; Colin O Wu; David A Bluemke; João A C Lima Journal: Circ Cardiovasc Imaging Date: 2018-03 Impact factor: 7.792
Authors: Monika Sarkar; Melissa Wellons; Marcelle I Cedars; Lisa VanWagner; Erica P Gunderson; Veeral Ajmera; Laura Torchen; David Siscovick; J Jeffrey Carr; James G Terry; Mary Rinella; Cora E Lewis; Norah Terrault Journal: Am J Gastroenterol Date: 2017-03-14 Impact factor: 10.864
Authors: L B VanWagner; M Serper; R Kang; J Levitsky; S Hohmann; M Abecassis; A Skaro; D M Lloyd-Jones Journal: Am J Transplant Date: 2016-03-29 Impact factor: 8.086